1,327 active trials 698 recruiting 168 Phase 3 601 sponsors 194 changes in 30 days
| Early Phase 1 | 15 | |
| Phase 1 | 140 | |
| Phase 1/2 | 136 | |
| Phase 2 | 485 | |
| Phase 2/3 | 16 | |
| Phase 3 | 152 | |
| Phase 4 | 20 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… | AstraZeneca | Recruiting | 2026-08-27 |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Recruiting | 2026-08-10 |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | 2026-08-10 |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… | Anhui Provincial Cancer Hospital | Recruiting | 2026-08-04 |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy… | Fujian Cancer Hospital | Recruiting | 2026-01-06 |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC… | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | 2025-07-29 |
| NCT06561620 | Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients | Fudan University | Recruiting | 2024-08-22 |
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in… | University of Crete | Recruiting | 2021-12-29 |
| NCT05144997 | Lorlatinib Continuation Study | Pfizer | Active, Not Recruiting | 2026-08-26 |
| NCT07671560 | Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant… | Qiming Wang | Not Yet Recruiting | 2026-06-26 |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor… | Centre Antoine Lacassagne | Not Yet Recruiting | 2026-06-08 |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | Guangdong Association of Clinical Trials | Active, Not Recruiting | 2026-04-09 |
| NCT05160922 | Crizotinib Continuation Clinical Study | Pfizer | Active, Not Recruiting | 2026-03-30 |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM)… | Shanghai Pulmonary Hospital, Shanghai, China | Not Yet Recruiting | 2026-03-13 |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance… | The First Affiliated Hospital of Guangzhou Medical University | Not Yet Recruiting | 2025-03-25 |
| NCT04413201 | AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib… | Michael Hopp | Active, Not Recruiting | 2025-03-25 |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable… | Fujian Medical University Union Hospital | Not Yet Recruiting | 2025-01-21 |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With… | Shanghai Chest Hospital | Not Yet Recruiting | 2024-08-30 |
| NCT06356675 | A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With… | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Not Yet Recruiting | 2024-04-10 |
| NCT06276933 | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment… | Tongji University | Not Yet Recruiting | 2024-02-26 |
| Phase 3 | ||||
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab… | Merck Sharp & Dohme LLC | Recruiting | 2026-08-27 |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Revolution Medicines, Inc. | Recruiting | 2026-08-27 |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum… | Amgen | Recruiting | 2026-08-27 |
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early… | National Cancer Institute (NCI) | Recruiting | 2026-08-25 |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Nuvalent Inc. | Recruiting | 2026-08-25 |
AstraZeneca (53) · Sun Yat-sen University (30) · Fudan University (28) · Shanghai Chest Hospital (27) · Shanghai Pulmonary Hospital, Shanghai, China (22) · Tianjin Medical University Cancer Institute and Hospital (22) · Hunan Province Tumor Hospital (19) · Merck Sharp & Dohme LLC (19) · Guangdong Association of Clinical Trials (18) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (15)